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T he potential for new approaches to the topical ther-apy of psoriasis has made another major step with the report by Rappersberger e/ at about an immunosup-pressive molecule that appears to be effective when administered topically. Since the serendipitous obser-
vation that the immunosuppressive drug, cyclosporin A (CSA), 
e.ffectively cleared psoriasis after systemic administration, an aggres-
Sive search has been pursued for ways to topically use this drug or 
a similarly functioning molecule. Topical CSA was shown to block 
experimental allergic contact dermatitis reactions in arumal skin 
models, possibly by easier penetration into that skin (1) . Numerous 
topical CSA preparations have f.,i led in man , however, despite 
efforts to improve penetration of the large CSA molecule (molec-
ular weight = 1203) (2). Alternatively, the mechanisms of CSA 
~ction may be somewhat different from other presumably similar 
Immunomodulatory drugs. When relatively large doses of painful 
intralesional injections provided only partial lesional clearing (at 
high doses) (3), it raised the question of whether CSA works by a 
local effect in the skin or a systemic interaction on target cells. A 
similar question has befuddled the potential use of topical metho-
trexa te (4). 
[n the current report a new macrolide of the ascomycin type 
(SDZ 281-240) has immunosuppresive actions similar to FK 506 
(Tacrolimus), a drug reported as systemically efficacious in psoriasis 
(5). Rappersberger c/ at believe, with only limited information in 
this study, that the molecule may have similar mechanisms of action 
to CSA. The major action would be to block the activation of 
T -cells by a "psoriasis antigen(s)," thereby suppressing the produc-
tion of lymphokines, particularly IL-2. These lymphokines appear 
to induce tbe hyperplasia of psoriatic keratinocytes leading to the 
clinical lesions of psoriasis. An ill vitro experiment in this study 
supports this hypothesis by showing that stimulated lymphocytes in 
m.ixed lymphocyte reactions are blocked from proliferation at 
extremely low concentrations of the drug (1.2 nM SDZ281-240) 
w llile HaCaT, a transformed human keratinocyte cell line, requires 
10,000 fold mOre drug to inhibit proliferation . The authors thus 
conclude that the drug's effect on eventually stopping the kerati-
nocyte hyperplasia comes by selectively blocking T-cell prolifera-
tion rather than a direct inhibition of keratinocytes. 
T he clinica.l trial in psoriasis with application of SDZ 281-240 to 
small plaques shows dramatic improvement of lesions by two 
concentrations of drug, 1% and 0.1 %, as well as a superpotent 
topical steroid, in comparison to minimal placebo effects. After 10 
days of therapy, all active preparations decreased the mean clinical 
score of 3 .0 to less than 0.5. In a variety of llistopathological and 
llnmunomorphological assays of pre- and post-treatment biopsies, 
many similar observations were made to those fo llowing systemic 
administration of CSA. InterestUlgly, most of the immunomorpho-
logical pa.rameters were also similar between the SDZ drug and the 
topical steroid therapy sites. Since many of these observations may 
reflect just the end resu lt of improvement rather than the primary 
mechanistic pathway(s), filrther studies will be needed to pinpoint 
the biochemical sites of action. The similarity of changes with both 
the study drug as an "inmlllnosuppressive agent" and the steroid as 
an "antiinflammatory agent," and both as "antiproliferatives, " 
should lead to many interesting concepts on how to tie this troika 
of actions together. The mode of action of SDZ281-240 as 
summarized by the authors would be a downregulation of activated 
T -cells, decreasing the cytokine-mediated proliferation of kerati-
nocytes that causes the psoriatic epidennis to return to a nomla.1 
proliferative and difFerentiated state with clinica.lly clear skin. 
For the psoriatic patient population, the great majority of whom 
have limited disease and use topical medications, a new and 
potentiaJly highly effective topical therapy would be a very wel-
come addition to the recent availability of calcipotriene and the 
probability of a topical retinoid, tazarotene, in the forseeable future. 
Many basic and clinical trials need to be done to ascertain the value 
of this drug including: the therapeutic uldex (benefit vs risk ratio); 
the optimal concentration (both concentrations used Ul this study 
were approximately equal Ul effect); potential of significant side 
effects, both topical and systemic; and importantly, the duration of 
effectiveness for long term maintainance without the concern of 
tachyphylaxis. This drug appears to be the first of a new generation 
of immunomodulating compounds that have the capability of 
altering the phenotype of psoriasis at the local level. Similarly, the 
drug may also be active at the local site of other inflammatory 
diseases, cutaneous, joint and elsewhere. 
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